ABIONYX Pharma Share Price Börse Stuttgart
Equities
609
FR0012616852
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.02 EUR | +2.10% | +2.78% | -43.40% |
14/03 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
11/03 | Abionyx: reduced net loss in 2023 | CF |
Sales 2023 | 4.6M 4.95M 413M | Sales 2024 * | 4.6M 4.95M 413M | Capitalization | 34.33M 36.96M 3.08B |
---|---|---|---|---|---|
Net income 2023 | -3M -3.23M -269M | Net income 2024 * | -6M -6.46M -539M | EV / Sales 2023 | 9.02 x |
Net cash position 2023 * | 100K 108K 8.98M | Net cash position 2024 * | 3.4M 3.66M 305M | EV / Sales 2024 * | 6.72 x |
P/E ratio 2023 * |
-7.61
x | P/E ratio 2024 * |
-7.11
x | Employees | 63 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 77.63% |
1 day | +6.51% | ||
Current month | -3.77% | ||
1 month | -3.77% | ||
3 months | -1.92% | ||
6 months | -1.92% | ||
Current year | -43.40% |
Managers | Title | Age | Since |
---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 01/07/01 |
Director of Finance/CFO | - | 01/08/01 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 09/15/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 06/15/06 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 01/07/01 |
Date | Price | Change | Volume |
---|---|---|---|
03/24/03 | 1.02 | +2.10% | 0 |
02/24/02 | 0.999 | +0.50% | 0 |
30/24/30 | 0.994 | +4.19% | 0 |
29/24/29 | 0.954 | -3.05% | 0 |
26/24/26 | 0.984 | +1.23% | 0 |
Delayed Quote Börse Stuttgart, May 03, 2024 at 06:56 pm IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-1.08% | 103B | |
+8.38% | 101B | |
+4.40% | 23.07B | |
-12.02% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.46% | 16.94B | |
+6.63% | 14.07B | |
+39.10% | 12.35B |
- Stock Market
- Equities
- ABNX Stock
- 609 Stock